(Q53770677)

19 May 2018

title

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. (English)

1 reference

19 May 2018

human subject research project

main subject

0 references

0 references

1 reference

3

Stephen J P Damment

1 reference

19 May 2018

Michael Pennick

series ordinal

1

object named as

Michael Pennick

1 reference

19 May 2018

author name string

Kerry Dennis

series ordinal

2

1 reference

19 May 2018

publication date

1 July 2006

1 reference

19 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

19 May 2018

volume

46

1 reference

19 May 2018

issue

7

1 reference

19 May 2018

page(s)

738-746

1 reference

19 May 2018

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Bile acid binding to sevelamer HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Evaluation of the potential genotoxicity of the phosphate binder lanthanum carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Lanthanum carbonate: a new phosphate binder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Lanthanum pharmacokinetics: are rat data misleading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

The need for careful interpretation of animal data on lanthanum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289846

21 January 2018

Identifiers

DOI

10.1177/0091270006289846

1 reference

19 May 2018

1 reference

19 May 2018